• Dose-Dependent Immune Dynamics in Porcine Deltacoronavirus I

  2026-05-26

  This study reveals how varying doses of porcine deltacoronavirus (PDCoV) distinctly modulate the host immune response in intestinal epithelial cells. By linking viral dose to the scale and nature of STAT1-driven antiviral and inflammatory pathways, the findings offer mechanistic insights for future immunomodulatory strategies against PDCoV.

• EGCG Nanoparticles Enhance FLASH-RT via DNA Damage and Immun

  2026-05-26

  This study demonstrates that functionalized self-assembled EGCG nanoparticles (BENPs) significantly boost the efficacy of ultra-high dose rate radiotherapy (FLASH-RT) by enhancing DNA double-strand breaks and antitumor immune responses. The findings suggest a promising strategy for improving cancer treatment outcomes while maintaining biosafety.

• 4-Phenylbutyric Acid: Optimizing ER Stress Assays in Kidney

  2026-05-25

  4-Phenylbutyric acid (4-PBA) streamlines ER stress modulation and cell death research with precise, reproducible workflows. Leverage APExBIO's high-purity reagent to achieve robust results in kidney injury models and beyond.

• RNA Pol II Inhibition Triggers Apoptosis Independent of Tran

  2026-05-25

  Harper et al. (2025) reveal that cell death following RNA Pol II inhibition arises from active apoptotic signaling—specifically due to the loss of hypophosphorylated RNA Pol IIA, not simply from loss of transcription. This finding redefines our understanding of regulated cell death and has significant implications for interpreting the effects of transcriptional inhibitors in apoptosis research.

• Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid): Mech

  2026-05-24

  Ibuprofen, a non-steroidal anti-inflammatory drug, acts as a dual COX-1/COX-2 inhibitor and demonstrates significant anti-proliferative effects in colon carcinoma research. This article details its atomic mechanisms, experimental benchmarks, and workflow guidance for advanced oncology and cardiovascular models.

• AG-490 (Tyrphostin B42): Disrupting Exosomal JAK2/STAT6 Sign

  2026-05-23

  Explore how AG-490 (Tyrphostin B42), a selective JAK2/EGFR inhibitor, empowers translational researchers to interrogate exosomal SNORD52-driven macrophage polarization in hepatocellular carcinoma. This article bridges the latest mechanistic insights with actionable experimental strategies, contextualizes AG-490’s competitive edge, and outlines a visionary path for immunopathology and cancer research.

• Annexin V-PE Reagent: Precision in Early Apoptotic Cell Dete

  2026-05-22

  Annexin V-PE Reagent streamlines early apoptosis detection through rapid, single-step staining and robust phosphatidylserine affinity. Its integration into flow cytometry and fluorescence microscopy workflows delivers high sensitivity and reproducibility, making it indispensable for apoptosis research in CAR-T and immunotherapy studies.

• Applied Workflows with EZ Cap™ Cre mRNA (m1Ψ) for Gene Editi

  2026-05-22

  EZ Cap™ Cre mRNA (m1Ψ) unlocks high-efficiency, low-immunogenicity Cre recombinase expression for advanced gene editing and functional studies, overcoming limitations of classical DNA or unmodified mRNA approaches. Its stability and translational advantages streamline extrahepatic delivery, especially in workflows leveraging next-generation nanoparticle carriers.

• Cell-Based HTS of HIV-1 Protease Autoprocessing: New Drug Di

  2026-05-21

  This study introduces a robust cell-based AlphaLISA assay for high-throughput screening of inhibitors targeting HIV-1 protease autoprocessing. By enabling precise evaluation of both drug efficacy and resistance, the platform advances our understanding of protease inhibition and supports translational research in antiviral drug development.

• Butyrate-Induced Ferroptosis Suppresses Lung Cancer Stemness

  2026-05-21

  This study reveals that butyrate reduces lung cancer stem cell characteristics by triggering ferroptosis through lysosomal Fe2+ accumulation and SLC7A11 degradation. The findings highlight a novel metabolic vulnerability in lung cancer stem cells and suggest new strategies for targeting tumor progression.

• Aminopeptidase Inhibition Specificity: Insights for ACE Inhi

  2026-05-20

  This article examines the re-evaluation of various metallopeptidase inhibitors, including ACE inhibitors, on mammalian cell surface aminopeptidases, based on the reference study. The work clarifies the selectivity profiles of these inhibitors and informs experimental design for disease models involving the renin-angiotensin system and related peptidase pathways.

• Itraconazole: Advanced Workflows for Candida Resistance Mode

  2026-05-20

  Itraconazole is redefining Candida research by targeting both fungal metabolism and cellular signaling pathways. This article delivers a stepwise protocol, troubleshooting insights, and actionable guidance for leveraging this triazole antifungal agent in drug resistance and biofilm assays.

• Angiotensin II Drives M1 Macrophage Polarization via Cx43/NF

  2026-05-19

  This study uncovers how Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) drives RAW264.7 macrophages toward a pro-inflammatory M1 phenotype through the connexin 43/NF-κB pathway, using a robust panel of molecular assays. The findings clarify a critical mechanism linking Angiotensin II to vascular inflammation and provide actionable targets for cardiovascular remodeling and hypertension mechanism research.

• SAR131675: Benchmark VEGFR-3 Inhibitor for Fibrosis and Tumo

  2026-05-19

  SAR131675 empowers researchers to dissect VEGFC/VEGFD pathways with nanomolar precision, offering selective inhibition for advanced lymphangiogenesis and tumor growth studies. Its rigorous selectivity, robust in vivo efficacy, and recent application in NASH fibrosis models make it a gold-standard anti-lymphangiogenic agent for translational research.

• Mitofusin 2 Regulates Angiotensin II-Induced Endothelial Sen

  2026-05-18

  This study uncovers how Angiotensin II drives endothelial cell aging by activating the STAT3–BCL6 axis, leading to reduced MFN2 and mitochondrial dysfunction. The findings clarify molecular links between vascular aging and hypertension, highlighting MFN2 as a potential therapeutic target.

16043 records 1/1070 page Next 12345 下5页 Last page